Adenocarcinoma of unknown primary site

There are no specific parameters to monitor in adenocarcinoma of unknown primary site (AUP). Standard re-assessment of the patient depends on the treatment protocol employed.[66]Seymour L, Bogaerts J, Perrone A, et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-52. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648544 http://www.ncbi.nlm.nih.gov/pubmed/28271869?tool=bestpractice.com [67]Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016 Jul;62:132-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737828 http://www.ncbi.nlm.nih.gov/pubmed/27189322?tool=bestpractice.com ​

Tumour markers (e.g., CEA and C19-9) can be used to assess treatment response in selected patients. However, baseline tumour markers are not recommended in all patients, due to their relative lack of specificity.

In general, patients receiving chemotherapy will be re-evaluated on a regular basis by repeated medical history-taking, physical examination, and dedicated laboratory or imaging tests that will allow assessment of response to treatment and guide subsequent decisions. These laboratory and imaging studies will be of the same modality as that used to make the initial assessment of the extent of disease, such as serum tumour marker level, or dimensions of a metastatic focus on computed tomography or magnetic resonance imaging.

Invasive testing is typically not employed for monitoring patients during or after treatment.